PD-1抑制剂在既往存在内分泌自身免疫患者中的免疫相关不良事件
本文报告两例接受抗PD-1单克隆抗体治疗的患者出现免疫相关不良事件:一例52岁男性在治疗3周后出现急性移植肾排斥反应,需接受血液透析,同时自身免疫性甲状腺功能减退加重;另一例62岁男性在治疗5天后发生严重糖尿病酮症酸中毒。结论指出,既往存在内分泌自身免疫的患者接受抗PD-1治疗时,免疫相关副作用可能更频繁、更严重。
要点
- 既往有内分泌自身免疫者接受抗PD-1治疗,免疫相关不良事件可能更频繁、更严重。
- 例1在开始抗PD-1治疗3周后出现急性移植肾排斥反应,需血液透析,同时自身免疫性甲状腺功能减退加重。
- 例2在开始抗PD-1治疗5天后发生严重糖尿病酮症酸中毒,尽管治疗前血糖和HbA1c正常,仍需永久性外源性胰岛素治疗。
核心结论
- 既往存在内分泌自身免疫的患者接受抗PD-1治疗时,免疫相关副作用可能更频繁、更严重。
- 鉴于实体器官移植排斥和糖尿病酮症酸中毒带来的疾病负担与死亡风险,临床医生应了解这类治疗的潜在不良事件。
研究设计与样本
- 本文为两例病例报告:一例为52岁男性,既往有长期1型糖尿病、长期稳定的肾移植和甲状腺功能减退,因转移性黑色素瘤接受两种不同的抗PD-1单克隆抗体治疗。
- 另一例为62岁男性,既往无糖尿病史,接受抗PD-1治疗后发生严重糖尿病酮症酸中毒。
主要发现
- 例1在开始抗PD-1治疗3周后出现急性移植肾排斥反应,需接受血液透析,同时自身免疫性甲状腺功能减退加重;他继续接受抗PD-1治疗,并维持血液透析和增加左甲状腺素剂量。
- 例2在开始抗PD-1治疗5天后发生严重糖尿病酮症酸中毒;进一步实验室检查发现抗谷氨酸脱羧酶高滴度抗体,为IgG同型并参与记忆免疫应答,很可能在抗PD-1治疗前已存在。
- 例2还携带赋予1型糖尿病遗传风险的人类白细胞抗原基因;尽管治疗前血糖水平和HbA1c正常,患者仍需永久性外源性胰岛素治疗。
关键数值与推荐
- 例1:52岁男性,既往有长期1型糖尿病、长期稳定肾移植和甲状腺功能减退,接受两种不同的抗PD-1单克隆抗体治疗转移性黑色素瘤;开始治疗3周后出现急性移植肾排斥反应(需血液透析)和自身免疫性甲状腺功能减退加重。
- 例2:62岁男性,既往无糖尿病史,开始抗PD-1治疗5天后发生严重糖尿病酮症酸中毒;检出抗谷氨酸脱羧酶高滴度IgG抗体,并携带赋予1型糖尿病遗传风险的人类白细胞抗原基因;治疗前血糖和HbA1c正常。
临床怎么用
- 临床医生在为接受抗PD-1治疗的患者提供诊疗时,应了解实体器官移植排斥和糖尿病酮症酸中毒等潜在不良事件。
- 对既往存在内分泌自身免疫的患者,接受抗PD-1治疗时需关注免疫相关副作用可能更频繁、更严重。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Immune checkpoint inhibitors, including monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, have emerged as beneficial cancer immunotherapies. These therapies are known to cause immune-related side effects; however, their role in patients with a preexisting autoimmune disease is not clear. CASE DESCRIPTION: We describe two cases of anti-PD-1 immune-related adverse events. A 52-year-old male with longstanding type 1 diabetes (T1D), long-term stable kidney transplant, and hypothyroidism received two separate anti-PD-1 monoclonal antibodies for metastatic melanoma. The patient developed acute kidney graft rejection requiring hemodialysis and worsening of autoimmune hypothyroidism 3 weeks after starting treatment. He continued anti-PD-1 treatments and remained on hemodialysis and increased levothyroxine dosage. The second case is a 62-year-old male with no previous history of diabetes who received anti-PD-1 treatment and developed severe diabetic ketoacidosis (DKA) 5 days following the start of therapy. Further laboratory testing revealed high titer antibodies directed against glutamic acid decarboxylase. These antibodies, which were of the IgG isotype and involved in memory immune responses, were likely present before anti-PD-1 treatment. He also had human leukocyte antigen genes that confer T1D genetic risk. Despite normal pretreatment blood glucose levels and HbA1c, the patient requires permanent exogenous insulin treatment. CONCLUSION: Patients with preexisting endocrine autoimmunity may have more frequent and severe immune-related side effects with anti-PD-1 treatment. Given the morbidity and mortality associated with solid organ transplant rejection and DKA, clinicians caring for patients receiving these state-of-the-art therapies need to be aware of the potential adverse events.
引用
- Akturk HK, Alkanani A, Zhao Z, et al. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. J Clin Endocrinol Metab. 2018. PMID: 30124874. doi:10.1210/jc.2018-01430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。